SCHEMBL4412475

SCHEMBL4412475

CCN1C(=O)N(c2ccc(F)c(O)c2F)Cc2cnc(NC3CCC(N)CC3)nc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 3/20 0.39
MAP4K2 Q12851 3/20 0.39
MAPK8 P45983 1/20 0.37
MAPK10 P53779 1/20 0.37
FGFR4 P22455 7/20 0.37
CDK7 P50613 2/20 0.36
CDK9 P50750 2/20 0.36
CCNK O75909 1/20 0.36
CSNK1A1 P48729 1/20 0.36
CDK13 Q14004 1/20 0.36
CDK12 Q9NYV4 1/20 0.36
FGFR1 P11362 1/20 0.36
MAPK14 Q16539 1/20 0.36
CDK1 P06493 1/20 0.35
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CDK2 P24941 1/20 0.35
MCHR1 Q99705 1/20 0.35
EGFR P00533 3/20 0.35
CSF1R P07333 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4399032 0.92 MAPK14 (0.43) TNK2MAP4K2MAPK8MAPK10FGFR4
SCHEMBL4544295 0.90 TNK2 (0.40) TNK2MAP4K2FGFR4FGFR1MAPK14
SCHEMBL4551241 0.87 FGFR4 (0.40) TNK2MAP4K2MAPK8MAPK10FGFR4
SCHEMBL4404536 0.86 EGFR (0.40) TNK2MAP4K2FGFR4FGFR1EGFR
SCHEMBL4411308 0.85 FGFR4 (0.41) FGFR4FGFR1MAPK14
SCHEMBL4407048 0.85 MAPK8 (0.41) TNK2MAP4K2MAPK8MAPK10FGFR4
SCHEMBL4411322 0.84 EGFR (0.45) TNK2MAP4K2FGFR4CDK7CDK9
SCHEMBL4407809 0.84 TNK2 (0.40) TNK2MAP4K2MAPK8MAPK10FGFR4
SCHEMBL4398479 0.82 FGFR4 (0.46) TNK2MAP4K2FGFR4FGFR1EGFR
SCHEMBL4395956 0.82 FGFR4 (0.40) TNK2MAP4K2MAPK8MAPK10FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
WO-2006038112-A1 USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS WARNER-LAMBERT COMPANY LLC (US) 2006-04-13 WO disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 TNK2 140/4885MAP4K2 54/4885MAPK8 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.